This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2025 Oct 13;15(1):161.

doi: 10.1038/s41408-025-01383-w.

Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

Tara Sebastian^#¹, Sridevi Rajeeve^#², Tasmin Farzana², Ross Firestone², Eric Jurgens², Kevin Miller², Bruno Almeida Costa¹, Alexander Lesokhin², Carlyn Rose Tan², Gunjan Shah², Neha Korde², Heather Landau², Michael Scordo², Hani Hassoun², Kylee Maclachlan², Urvi Shah², Malin Hultcrantz², Andriy Derkach³, Derkach Nemirovsky³, Sergio Giralt², Saad Usmani², Sham Mailankody², Hamza Hashmi⁴

Affiliations

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Division of Epidemiology and Biostatistics, Department of Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hashmih1@mskcc.org.

^# Contributed equally.

PMID: 41083445
PMCID: PMC12518869
DOI: 10.1038/s41408-025-01383-w

Published Erratum

Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

Tara Sebastian et al. Blood Cancer J. 2025.

. 2025 Oct 13;15(1):161.

doi: 10.1038/s41408-025-01383-w.

Authors

Tara Sebastian^#¹, Sridevi Rajeeve^#², Tasmin Farzana², Ross Firestone², Eric Jurgens², Kevin Miller², Bruno Almeida Costa¹, Alexander Lesokhin², Carlyn Rose Tan², Gunjan Shah², Neha Korde², Heather Landau², Michael Scordo², Hani Hassoun², Kylee Maclachlan², Urvi Shah², Malin Hultcrantz², Andriy Derkach³, Derkach Nemirovsky³, Sergio Giralt², Saad Usmani², Sham Mailankody², Hamza Hashmi⁴

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Division of Epidemiology and Biostatistics, Department of Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. hashmih1@mskcc.org.

^# Contributed equally.

PMID: 41083445
PMCID: PMC12518869
DOI: 10.1038/s41408-025-01383-w

No abstract available

PubMed Disclaimer

Erratum for

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Sebastian T, Rajeeve S, Farzana T, Firestone R, Jurgens E, Miller K, Costa BA, Lesokhin A, Tan CR, Shah G, Korde N, Landau H, Scordo M, Hassoun H, Maclachlan K, Shah U, Hultcrantz M, Derkach A, Nemirovsky D, Giralt S, Usmani S, Mailankody S, Hashmi H. Sebastian T, et al. Blood Cancer J. 2025 Aug 14;15(1):137. doi: 10.1038/s41408-025-01343-4. Blood Cancer J. 2025. PMID: 40813765 Free PMC article. No abstract available.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central